These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment. Vella LJ; Andrews MC; Behren A; Cebon J; Woods K Expert Rev Clin Immunol; 2014 Aug; 10(8):1107-23. PubMed ID: 24939732 [TBL] [Abstract][Full Text] [Related]
10. Molecular targeted therapy in melanoma: a way to reverse resistance to conventional drugs. Maira F; Catania A; Candido S; Russo AE; McCubrey JA; Libra M; Malaponte G; Fenga C Curr Drug Deliv; 2012 Jan; 9(1):17-29. PubMed ID: 22023213 [TBL] [Abstract][Full Text] [Related]
11. [What's new in skin cancers?]. Jouary T Ann Dermatol Venereol; 2014 Dec; 141 Suppl 4():S630-42. PubMed ID: 25539755 [TBL] [Abstract][Full Text] [Related]
12. Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists. Kakavand H; Wilmott JS; Long GV; Scolyer RA Pathology; 2016 Feb; 48(2):194-202. PubMed ID: 27020392 [TBL] [Abstract][Full Text] [Related]